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1. Introduction 
L-carnitine is suggested as a potential therapeutic agent in metabolic encephalopathies, such 
as ammonia-precipitated hepatic encephalopathy (HE). In humans, ammonia is produced 
mainly by the metabolism of proteins and amino acids. Most of the ammonia is detoxified 
by the urea cycle which is located in the liver. Thus, disturbances of the urea cycle in the 
liver lead to higher ammonia levels in blood. In humans, hyperammonemia (HA) arises 
mainly from liver diseases and is in most cases associated with HE. There are currently only 
a few therapeutic strategies, and outcome expectations for patients with HE are poor. L-
carnitine and its acyl-derivates are suggested as potential and low-cost therapeutic agents. 
In animal models, L-carnitine has been shown to counteract neurotoxic effects of ammonia, 
increase energy metabolism and decrease mortality. A protective effect against ammonia-
precipitated HE has also been observed in cirrhotic patients. A review of the literature offers 
in vitro and in vivo studies, as well as human trials with promising results. This chapter 
provides a comprehensive summary and a summarized discussion of the literature data 
concerning the effects of L-carnitine, with special emphasis on hyperammonemic syndromes 
and HE.  
L-carnitine is essential for the transfer of long-chain fatty acids from the cytoplasm to the 
inner mitochondrial membrane, thereby facilitating mitochondrial energy metabolism. By 
virtue of their metabolic functions and neurophysiological roles, L-carnitine and its 
acetylated derivates are suggested as a therapeutic agent in several neurological disorders, 
including HE. In the brain, they have important roles in cerebral bioenergetics and 
neuroprotection through a variety of mechanisms including their antioxidant properties by 
modulation and promotion of synaptic neurotransmission. However, questions remain as to 
its systemic vs. cerebral effects, its relative effects on astrocytes and neurons, and its clinical 
use.  
High-resolution Nuclear Magnetic Resonance (NMR) approaches using stable isotopes are 
now yielding large amounts of detailed information on cerebral metabolic 
compartmentalization and neuronal-glia interactions (Zwingmann & Leibfritz, 2003). In 
order to investigate the effect of L-carnitine on energy- and fatty acid metabolism, 1H- and 
13C-NMR spectroscopy was used to measure metabolic pathways in brain and muscle 
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following administration of [U-13C]glucose to rats with mild HE and in rats with ammonia-
precipitated encephalopathy. As a model of mild HE, we investigated rats four weeks after 
an end-to-side portacaval anastomosis (PCA). PCA in the rat resulted in a broad spectrum of 
neurobehavioral changes, such as an 80% impaired locomotor activity, which was largely 
prevented by L-carnitine. Concomitantly, L-carnitine improved mitochondrial energy 
metabolism in brain and muscle. In ammonia-precipitated encephalopathy, L-carnitine 
considerably delayed the rats’ time to coma, concomitantly with a prevention of ammonia-
induced increased lactate synthesis in the brain. These results demonstrate that in HE, L-
carnitine acts both in the brain and in the muscle not by improving ammonia removal but 
by improving mitochondrial metabolism. These mechanisms explain L-carnitine’s 
therapeutic benefit in the prevention of mild HE and ammonia-precipitated encephalopathy 
in cirrhotic patients. Since it is a low-cost agent with few side effects, further clinical trials 
could be promising in evaluating the broader use of L-carnitine and derivatives in patients 
with HE. 
2. Hyperammonemia 
The gut bacterial flora are responsible for the production of ammonia, the end-product of 
bacterial protein metabolism. The proteins that are metabolized by bacteria originate from 
exogenous alimentary sources (e.g. meat) or from endogenous sources (e.g. gastro-intestinal 
hemorrhage) (Hoyumpa et al., 1979). After ammonia is generated, ammonia can be 
detoxified by the formation of amino acids in the liver or in extrahepatic organs. One 
important mechanism is the synthesis of glutamine from glutamate and ammonia in the 
muscle (Fig. 1). The glutamine derived from muscle can be used as an energy substrate in 
the gut and is also transported to the kidney, where it is hydrolyzed to glutamate and 
ammonia. In the kidney, ammonia is detoxified by urea synthesis, which is released by the 
urine. Portal vein ammonia is present at a very high concentration. It is transported through 
the portal circulation to the liver, where it is normally converted to urea through the urea 
cycle and subsequently released by the kidney (McDermott, 1957). In liver diseases, the 
normal ammonia detoxification mechanisms may be compromised, and excess ammonia 
enters the brain. Furthermore, as it can occur in chronic cirrhosis or construction of a 
portacaval shunt, the shunting of the blood passing the liver will greatly increase systemic 
ammonia concentrations, which may then enter the central nervous system (CNS) 
(Butterworth et al., 1987; Lockwood et al., 1979). Since the brain lacks an effective urea cycle, 
basically the only mechanism to detoxify ammonia is conversion to glutamine through 
glutamine synthetase (GS). In the CNS, GS is localized almost exclusively in the astrocytes 
(Norenberg & Martinez-Hernandez, 1979). 
The metabolic conversion system that leads to the production of urea is highly efficient, and 
under healthy conditions it is unlikely to become hyperammonemic. HA is not a true 
disease; it is a sign that specific abnormalities, e.g. urea cycle disorders and liver diseases, 
that cause blood ammonia levels to become elevated may be present.  
HA is considered a key factor in HE, which is defined as a spectrum of neuropsychiatric 
abnormalities in patients with liver dysfunction, after other known brain disease has been 
ruled out. In the brain, high ammonia levels modify several amino acid pathways and 
neurotransmitter systems, as well as cerebral energy metabolism, nitric oxide synthesis, 
antioxidant systems, mitochondrial permeability transition and signal transduction 
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pathways. HE due to both chronic liver failure (CLF) and acute liver failure (ALF) is 
manifested by neuropathological changes that primarily affect astrocytes. The main 
pathological manifestation in CLF and chronic HA is the appearance of Alzheimer type II 
astrocytosis (Norenberg, 1977, 1987). In HA and HE due to ALF, death most frequently 
results from brainstem herniation due to increased intracranial pressure as a result of a 
progressive increase of brain water content (brain edema) due to astrocyte swelling (Blei, 
2001; Butterworth, 1998; Chung et al., 2001; Cordoba & Blei, 1995; Larsen et al., 2001). 
Among other mechanisms, ammonia-induced disturbances in the synthesis and degradation 
of the neuronal neurotransmitter amino acid glutamate lead to changes in its brain levels as 
well as in its reuptake by astrocytes (Butterworth, 2002; Michalak et al., 1996). The resulting 
excitotoxic levels in the cerebrospinal fluids (CSF) can lead to an overactivation of 
glutamatergic receptors on the postsynaptic neuron.  
 
Fig. 1. Development of hyperammonemia. The production of ammonia in the 
gastrointestinal tract occurs as a result of the action of bacteria on nitrogenous substances, as 
well as gastrointestinal bleeding. After ammonia is generated, the principal fate is 
incorporation into glutamine in extrahepatic organs, such as the muscle. The glutamine 
derived from muscle acts as an energy source for the gut and at the same time releases 
ammonia for urea synthesis in the kidney. Portal vein ammonia, on the other hand, which is 
present at a much higher concentration, is largely detoxified as urea in the liver and released 
by the kidney. When the liver fails due to dysfunction or shunting of the portal venous 
blood, large amounts of ammonia enter the brain. Basically the only way to detoxify 
ammonia in the brain is by synthesis of glutamine. 
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The neuronal N-methyl-D-aspartate (NMDA) receptor is a glutamatergic ionotropic 
receptor, and elevated ammonia levels lead to an excessive activation of this receptor (Cauli 
et al., 2008; Monfort et al., 2002). This induces an increased expression of the neuronal nitric 
oxide synthase (nNOS) producing nitric oxide (NO). NO reduces the activity of antioxidant 
enzymes, leading to increased formation of superoxides and therefore to oxidative stress 
(Kosenko et al., 1998, 1999). NO can also interact with superoxide anions to form 
peroxynitrite, which is a powerful nitration reagent. It nitrates tyrosine residues in proteins, 
including enzymes such as GS (Rose & Felipo, 2005), resulting in an inhibition of their 
activity. Another consequence of oxidative stress is the activation of mitogen-activated 
protein kinases (MAPKs). The kinases are key substances of intracellular signaling cascades, 
which control a number of cellular responses to extracellular impulses. Increased ammonia 
levels lead to phosphorylation of these enzymes, and recent studies suggest the involvement 
of MAPK phosphorylation in the mechanisms of ammonia-induced astrocyte dysfunction 
and cell swelling (Jayakumar et al., 2006). 
The energy metabolism of the CNS is affected by ammonia in different ways. Increased 
ammonia levels have been suggested to inhibit the tricarboxylic acid (TCA) cycle enzyme ǂ-
ketoglutarate dehydrogenase (Lai & Cooper, 1986). More recently, a direct effect of 
ammonia on neuronal pyruvate dehydrogenase (PDH) has been proposed by NMR studies 
(Chatauret et al, 2003; Zwingmann et al., 2003). PDH is a mitochondrial matrix multienzyme 
complex that provides the link between glycolysis and the TCA cycle by catalyzing the 
conversion of pyruvate into acetyl-CoA. If PDH, and subsequently mitochondrial energy 
production, is compromised, a switch to glycolysis may in part compensate by cytosolic 
ATP production. As a result, and to maintain reduced equivalents needed for glycolytic 
conversion of glucose, lactate dehydrogenase (LDH) converts pyruvate to lactate which 
accumulates (Kala & Hertz, 2005; Zwingmann et al., 2003, 2007; Zwingmann & Butterworth, 
2005). On the other hand, the stimulation of the glycolytic enzyme phosphofructokinase by 
ammonia (Ratnakumari & Murthy, 1993) also leads to elevated lactate levels. Consistent 
with these possibilities, brain lactate concentrations have been consistently found to be 
increased in brain and extracellular fluid of various animal models of acute HA (Bates et al., 
1989; Deutz et al., 1988; Holmin et al., 1983; Michalak et al., 1996; Peeling et al., 1993), as well 
as in patients with ALF (Tofteng & Larsen, 2002). Previous studies have shown that, like 
ammonia, lactate exposure to cultured astrocytes also results in significant cell swelling 
(Staub et al., 1990). 
While ammonia may impair mitochondrial glucose oxidation, some of the 
neuropathological manifestations in hyperammonemic states in liver failure may be 
mediated by the accumulation of astrocytic glutamine as a result of ammonia detoxification 
(Norenberg et al., 2007). While the osmotic effect of glutamine might not be the primary 
cause of astrocyte swelling, its accumulation has been shown to have secondary effects on 
astrocyte function, energy metabolism and neurotransmitter homeostasis. For example, 
glutamine, as well as ammonia itself, can induce the mitochondrial permeability transition 
(Rama Rao et al., 2003). The increased permeability can lead to elevated levels of osmolytes 
in the astrocytes and subsequent to a collapse of the mitochondrial inner membrane 
potential, resulting in mitochondrial dysfunction and enhanced free radical production 
(Norenberg et al., 2007). Increased levels of both glutamine and lactate, as well as changes in 
membrane permeability, can contribute to an enhanced water influx into the astrocytes and 
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thereby to swelling of the cells (Bachmann, 2002; Chatauret et al., 2003; Norenberg et al., 
1998; Rama Rao et al., 2003). Specifically in acute disease states, astrocyte swelling is a major 
cause of cerebral edema and intracranial hypertension, leading to encephalopathy, coma 
and death. 
3. Hepatic encephalopathy 
HE is a clinical manifestation due to CLF or ALF. HE is classified according to the West 
Haven Criteria. These define HE grade I to IV, based on the presence of specific clinical 
signs and symptoms and their intenseness (Ferenci et al., 1998). Manifest encephalopathy is 
characterized by neuropsychiatric symptoms ranging from mild personality changes and 
impairment of consciousness, attention span and orientation (grade I) to deep coma (grade 
IV). It is diagnosed by clinical signs, neuropsychiatric evaluations and neuroimaging 
methods. Patients with minimal HE show no significant symptoms of brain dysfunction, but 
it can have a far-reaching impact on quality of life, ability to function in daily life and 
progression to overt hepatic encephalopathy. For example, many patients with minimal HE 
show an impaired ability to drive a motor vehicle (Wein et al., 2004). The diagnosis of 
minimal HE is primarily carried out by the flicker test (Kircheis et al., 2002a). The critical 
flicker frequency (CFF) analysis is an objective and reproducible assay of HE severity. It 
defines the frequency at which light pulses are perceived as fused or flickering light. The 
technique shows little dependence upon age, education or training and is even able to detect 
minimal encephalopathy. 
HA is considered to be a key factor in both forms of liver failure, but its relation to 
neurological damage in HE is poorly understood. Furthermore, there are other precipitating 
factors in HE, such as elevated manganese, hyponatraemia, inflammatory cytokines and 
benzodiazepine-type sedatives (Cordoba & Minguez, 2008; Haeussinger & Schliess, 2008). 
HE occurs mostly as a result of a chronic disease. The current epidemic of hepatitis C, for 
example, emphasizes the importance of this clinical problem, particularly with regard to the 
extremely high mortality rate of 80-90% (Schiodt et al., 1999). However, HE development 
also appears acutely in previously healthy individuals due to viral hepatitis or overexposure 
to hepatotoxins like acetaminophen. While the chronic form of HE progresses slowly, rapid 
deterioration in consciousness level and death usually occur in the acute form of HE. 
3.1 Therapeutic means in Hepatic encephalopathy  
There are different therapeutic means of treating patients with HE. One possibility is a liver 
support device and liver transplantation, a definitive therapeutic strategy that improves 
outcomes in patients. However, there are several drugs being examined in research and 
clinical trials that could benefit patients with HE. Most of them tend to reduce the 
production and absorption of ammonia from the colon (Bass, 2007; Morgan et al., 2007). 
Furthermore, non-absorbable disaccharides inhibit bacterial ammonia production in the 
colon and retard ammonia as non-diffusable ammonium in the intestinal colon (Cammà et 
al., 1993). But in many cases, studies approving the efficacy and safety of the drugs are 
limited (Bass, 2007). Antibiotics are administered to reduce the quantity of enteric bacteria 
which produce ammonia. For example, rifaximin seems to be more effective than other 
antibiotics and is inexpensive (Leevy & Phillips, 2007). 
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Also, substances modifying ammonia metabolism are considered as therapeutic means in 
HE. Commonly used pharmacologic agents to treat HA are sodium phenylacetate and 
sodium benzoate, which can serve as alternatives to urea for nitrogen excretion. 
Phenylacetate conjugates with glutamine, a major detoxification product of ammonia, to 
form phenylacetylglutamine, which is excreted by the kidney. Sodium benzoate, on the 
other hand, reduces ammonia levels in blood because it is metabolized to hippurate by 
conjugation with glycine, which is rapidly excreted by the kidney (Morgan et al., 2007). 
A primary liver function is the regulation of amino acid supply to peripheral tissues. In HE, 
an increase of aromatic amino acids compared to branched-chain amino acids has been 
observed, which could be modified by the intake of branched-chain amino acids (Bass, 
2007). Also L-Ornithine-L-Aspartate lowers ammonia levels in blood as it provides 
substrates for the metabolic conversion of ammonia to urea and glutamine (Kircheis et al., 
2002b). Another means of treating HA is restriction of dietary protein (a source of 
ammonia), while caloric intake is provided by glucose and fat. Less investigated to date are 
L-carnitine and its derivatives, which are suggested to increase fat metabolism and have 
been suggested to decrease ammonia concentrations in blood by raising metabolic energy 
production (Bass, 2007).  
4. L-carnitine  
L-carnitine (L-4-N-trimethylammonium-3-hydroxybutyric acid) is known to be involved in 
long-chain fatty acid metabolism. The quatenary amine is synthesized in the liver and 
kidney from lysine and methionine (Bremer, 1983; Steiber et al., 2004). However, the major 
part of the daily requirement is covered by dietary intake. For example, food of animal 
origin, particularly red meat, contains significant amounts of L-carnitine (Steiber et al., 
2004). 
L-carnitine is essential for the transfer of long-chain fatty acids from the cytoplasm to the 
inner mitochondrial membrane for their oxidation (Fig. 2). Fatty acids are released from 
adipose tissue into the plasma. There, they are bound to albumin and carried to muscles, 
where a membrane transporter yields them into the cytoplasm. In the cytoplasm the fatty 
acids are activated by conjugation to Coenzyme A by means of Coenzyme A synthase. The 
acyl group from acyl-CoA is then transferred to the inner aspect of the outer mitochondrial 
membrane via the L-carnitne palmitoyl transferase I (CPTI) where it is linked to L-carnitine. 
The acylcarnitine is subsequently translocated across the inner mitochondrial membrane by 
the carnitine-acylcarnitine translocase (CACT). In the mitochondrial matrix acylcarnitine is 
reconverted to acyl-CoA and L-carnitine through carnitine palmitoyl transferase II (CPTII). 
The released L-carnitine is returned to the cytoplasm via carnitine palmitoyltransferase II, 
while the acyl-CoA can be metabolized through ǃ-oxidation to acetyl-CoA (Bremer, 1983; 
Luppa, 2004; Virmani & Binienda, 2004). The ǃ-oxidation of fatty acids is important because 
it provides acetyl-CoA, a substrate for the TCA cycle. Thus, decreased intramitochondrial 
transport of fatty acids due to carnitine deficieny can lead to an inhibition of mitochondrial 
pyruvate oxidation in the TCA cycle. Since the reaction of the carnitine palmitoyl transferase 
is reversible, it is possible to release acetylcarnitine from the mitochondria into the plasma. 
Therefore, L-carnitine acts as a buffer for the acetyl-CoA/CoASH ratio (Luppa, 2004; Steiber 
et al., 2004) and activates the mitochondrial respiration rate.  
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Fig. 2. Suggested action of L-carnitine. L-carnitine can facilitate the entry of fatty acids into 
the mitochondria. These fatty acids can be used to produce energy. A) Fatty acids must first 
be activated in the outer mitochondrial membrane before they can be used. Acetyl-CoA 
synthetase activates the fatty acid and transforms it to acyl-CoA. B) Activated fatty acids in 
the form of acyl-CoA are carried across the mitochondrial membrane by L-carnitine.  
L-carnitine is recycled back. In the mitochondria, acyl-CoA undergoes -oxidation to 
produce acetyl-CoA, which is used for mitochondrial energy production in the TCA cycle. 
4.1 L-cartinine in the CNS 
Tissue that copes with its energy demands by fatty acid oxidation, i.e. liver, muscles, kidney 
and heart, contains high levels of L-carnitine. Significant amounts of L-carnitine are also 
localized in the brain. Although the main energy production in the brain occurs by 
mitochondrial glucose oxidation, it has been observed that at least part of the cerebral 
energy production from acetyl-CoA occurs via fatty acid oxidation, most notably in 
astrocytes (Ebert et al., 2003). Another major task of L-carnitine in the brain is the transfer of 
acetyl-CoA from the mitochondria into the cytoplasm (see above). By this means acetyl-CoA 
also provides acetyl groups for the synthesis of the neurotransmitter acetylcholine. In 
addition, L-carnitine and its acylderivates can change the activity of certain proteins such as 
cysteine aspartic acid specific proteases (caspases) (Mutomba et al., 2000). They are also able 
to modify membrane fluidity and surface charge and therefore alter the activity of several 
enzymes and transporters that are located in the membrane (Nałecz et al., 2004; Virmani & 
Binienda, 2004). L-carnitine and its acylderivates may also increase the synthesis of 
phospholipids, which are required for membrane formation and integrity, and thereby 
modulate neuronal activity (Virmani & Binienda, 2004). 
There are two known forms of L-carnitine deficiency, the primary systemic and the 
secondary deficiency. Primary systemic L-carnitine deficiency is caused by several defects in 
the biosynthesis and transport of L-carnitine. This leads to increased excretion of L-carnitine 
and decreased L-carnitine accumulation in tissues (Longo et al., 2006, Vielhaber et al., 2004). 
Secondary L-carnitine deficiency occurs due to genetically defined disturbances in fatty acid 
oxidation and amino acid homeostasis. Several medical conditions, such as cirrhosis and 
other metabolic disorders, lead to secondary L-carnitine deficiency, as well as hemodialysis 
or kidney failure (Fornasini et al., 2007, Virmani & Binienda, 2004). Both disorders induce 
the same symptoms, like periodic encephalopathies which often come along with 
fatty acid acyl-CoA
acyl-CoA + carnitine
carnitine
acyl-CoA
CPDI
translocase
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hypoglycemia and hypoketonia. Other symptoms are hypotonia, weakness, episodes of 
coma, seizures, neuropathy and anemia. 
4.1.2 Pharmaceutical use of L-carnitine in brain disorders 
By virtue of their metabolic functions and neurophysiological roles, L-carnitine and its 
acetylated derivates are suggested as a therapeutic agent in several neurological disorders. 
Among others, the effects of L-carnitine and its derivates have been investigated in 
Alzheimer's disease, chronic fatigue syndrome, Parkinson’s disease, and neuropathic pain, 
as well as in valproic acid intoxication associated with CNS depression and raised ammonia 
levels without hepatotoxicity (Beal, 2003; Chan et al., 2007; Kuratsune et al., 2002; Pittler 7 
Ernst, 2008; Silva et al., 2008). Fatty acid metabolism plays a major role in brain energy 
metabolism since acetyl-CoA enters the mitochondrial TCA cycle via PDH in both astrocytes 
and neurons (Fig. 3).  
 
Fig. 3. Formation of acetyl-CoA from glucose and fatty acids. Glycolysis transforms glucose 
into pyruvate. Pyruvate may enter the TCA cycle via the anaplerotic pathway (PC; EC 
6.4.1.1) or the oxidative pathway (PDH; EC 1.2.4.1) through acetyl-CoA. Acetyl-Coa can also 
be formed from fatty acids after the entry of acyl-CoA from the cytosol into the 
mitochondria, a process which is facilitated by L-carnitine. 
In cerebral diseases, where mitochondrial dysfunction, impaired energy metabolism and 
oxidative stress play a decisive role for their development, such as in Parkinson' s disease, L-
carnitine has been shown to improve overall metabolic activity by yet unknown mechanism 
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(Beal, 2003, Zhang et al., 2008). Also, in vitro models have shown significant improvements 
of mitochondrial biogenesis when L-carnitine is given in combination with other 
mitochondrial nutrients, such as R-ǂ-Lipoic acid (Zhang et al., 2008).  
In the brain, both L-carnitine and acetyl-L-carnitine play further important roles in cerebral 
bioenergetics and neuroprotection through a variety of mechanisms, including their 
antioxidant properties through the modulation and promotion of synaptic 
neurotransmission (Inazu & Matsumiya, 2008). Alzheimer's disease and chronic fatigue 
syndrome occur mainly in the elderly. L-carnitine and its derivates can restore changes in 
membrane phospholipid metabolism found in subjects with Alzheimer’s disease 
(Montgomery et al., 2003; Pettegrew et al., 2000). Furthermore, it is able to enhance quality 
of life in patients with Alzheimer's disease and chronic fatigue syndrome because of its 
cholinergic function and stimulation of cellular energy production (Malaguarnera et al., 
2007, 2008; Pettegrew et al., 2000). Acetyl-L-carnitine has also been successfully applied as a 
pharmacological agent for the treatment of chronic degenerative diseases of the senile brain 
and for slowing down the progression of mental deterioration in Alzheimer's disease. The 
mechanisms may involve both the cholinergic neuronal transmission activity of acetyl-L-
carnitine and its ability to enhance neuronal metabolism in mitochondria (Inazu & 
Matsumiya, 2008). Neuropathic pain has several causes, such as diabetes polyneuropathy, 
HIV, or chemotherapeutic agents. In these cases, acetyl-L-carnitine has been shown to have 
an analgesic effect due to its cholinergic action. Moreover, it is able to improve nerve 
function by activating several receptors via acetylation (Chiecho et al., 2007, Sima, 2007). 
Valproic acid is a broad-spectrum antiepileptic drug which is known to reduce L-carnitine 
level, and can lead to HA. It has been suggested that L-carnitine may decrease ammonia 
levels by binding to valproic acid (Chan et al., 2007, Lheureux et al., 2005, Wadzinski et al., 
2007). 
4.1.2.1 L-carnitine in experimental hyperammonemia 
HA can be induced in animal models by several approaches. Major common methods are to 
inject neurotoxic amounts of ammonium acetate or to feed the animals a high ammonia diet. 
Several studies have demonstrated that L-carnitine can prevent acute ammonia toxicity and 
decrease its effects on the brain. O’Connor et al. (1984 a, 1984 b) injected L-carnitine in mice 
30 min before administration of a lethal dose of ammonia acetate. They demonstrated that L-
carnitine reduces mortality (100% survival with 12 mmol/kg body weight) and prevents 
symptoms of ammonia toxicity. Survival and beneficial effects depended on the dose of L-
carnitine. From these data, it was suggested that the protective effect of L-carnitine is based 
on significant improvements in the cellular redox state and mitochondrial energy 
metabolism. The concomitant decrease in blood and brain ammonia concentrations was 
proposed to be due to activation of the urea cycle by L-carnitine via carbamyl phosphate 
synthetase. I Matsuoka & Igisu (1993a) compared the effects of L-carnitine, D-carnitine and 
acetyl-L-carnitine in the therapy of acute HA in mice. Marked alterations were observed in 
brain energy metabolites after ammonia injection, which were suppressed by all three 
substances together with reduced blood and brain ammonia levels and a reduction in the 
frequency of seizures. Interestingly, acetyl-L-carnitine better conserved adenonsine-
triphosphate (ATP) in the brain, while it reduced ammonia levels in the blood and brain less 
markedly. These results suggest that the protective actions of L-carnitine and its derivates 
are systemic, and that the effect of acetyl-L-carnitine differs from that of L-carnitine. In a 
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previous study, the authors injected mice with sublethal doses of ammonium acetate to rule 
out the effects of seizures on brain energy metabolism (Matsuoka and Igisu, 1993b). These 
data further showed that L-carnitine improves brain energy metabolism in experimental HA 
in a systemic manner and not by suppression of seizures. Another study investigated the 
effects of different L-carnitine doses on cerebral and hepatic energy metabolites in 
hyperammonemic sparse-fur (spf) mutant mice with X-linked ornithine transcarbamylase 
deficiency, a model of congenital chronic HA. It was shown that L-carnitine is able to 
activate the fatty acid oxidation during sodium benzoate treatment (Ratnakumari et al., 
1993b). Sodium benzoate reduces ammonia levels through hippurate formation. A possible 
side effect is decreased levels of acetyl-CoA due to formation of benzoyl-CoA, while L-
carnitine was able to restore the availability of free CoA and thereby could reduce ammonia 
levels and improve energy metabolism. Subsequently, Ratnakumari et al. (1995) studied the 
effect of acetyl-L-carnitine on the development of cerebral cholinergic parameters in the 
same mouse model of HA. Cholinergic deficiency in hyperammonemic mice was 
significantly improved by treatment with acetyl-L-carnitine. The reason for the restoration 
could be an L-carnitine induced elevation of nerve growth factor levels and activation of 
choline acetyltransferase (Ratnakumari et al., 1995). In the study by Rao and Qureshi (1999), 
HA led to an excessive release of glutamate, which in turn resulted in upregulation of the 
NMDA receptor. The cellular reuptake of glutamate depends on sufficient availability of 
ATP levels. The results of this study demonstrated that acetyl-L-carnitine modulates the 
binding sites of the NMDA receptor, while enhanced ATP production via the TCA cycle, 
activated by acetyl-L-carnitine, might have contributed to stimulated uptake of glutamate 
from the extracellular fluid. 
A model of ammonia-precipitated encephalopathy is the portacaval-shunted rat receiving 
ammonium acetate (Belanger and Butterworth, 2005). In this model, Therrien et al. (1997) 
examined the effect of L-carnitine (16 mmol/kg, intraperitoneally), given 1 hour before 
ammonium acetate (8.5 mmol/kg, subcutaneously) to portacaval shunted rats. 
Hyperammonemic rats manifested severe encephalopathy progressing through loss of 
righting reflex to coma, and the survival rate was 5%. Similar to the study by O'’Connor et 
al. (1984), none of the L-carnitine treated animals died or showed neurological impairments. 
However, L-carnitine pretreatment did not substantially reduce plasma ammonia levels or 
increase CSF or brain glutamine levels in these rats, while it reduced CSF ammonia. 
Interestingly, L-carnitine reduced ammonia-induced increases in CSF lactate and alanine, 
suggesting an improvement of cerebral mitochondrial energy metabolism. According to the 
studies mentioned above, L-carnitine exerts protective effects against cerebral energy 
distortions and neuronal dysfunction in HE.  
4.1.2.1.1 L-carnitine in in vitro ammonia toxicity 
In addition to experimental animals with HA, studies were performed in hippocampal slices 
and cultured neurons to evaluate some mechanistic aspects of the effect of L-carnitine. Many 
of the cerebral effects of ammonia have been explained by extracellular glutamate 
accumulation and NMDA receptor activation by both ammonia or glutamate. In primary 
neurons, for example, it has been demonstrated that L-carnitine prevented glutamate 
neurotoxicity in a dose-dependent manner similar to that required to prevent ammonia 
toxicity in animals, and decreased the affinity of glutamate for the NMDA receptor (Felipo 
et al., 1994). In a study by Llansola et al. (2002), treatment of primary neurons in culture with 
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1 mM glutamate caused cell death of 80%. In this system glutamate neurotoxicity was 
mainly mediated by activation of NMDA receptors. The addition of 1 mM L-carnitine 15 
min before glutamate prevented neuronal death caused by glutamate. Furthermore, L-
carnitine increased the binding affinity of glutamate for metabotropic glutamate receptors, 
which was reversed if metabotropic glutamate receptors were blocked with specific 
antagonists (Llansola et al., 2002). Further studies in primary cultured neurons also 
indicated that L-carnitine interferes with NMDA-induced, NO mediated activation of MAP 
kinase at a step subsequent to NO formation (Llansola & Felipo, 2002). However, as 
mentioned above, recent studies suggest that MAPK phosphorylation is also involved in the 
mechanisms of ammonia-induced astrocyte dysfunction and cell swelling (Jayakumar et al., 
2006). In rat hippocampal slices, L-carnitine was able to reverse some of the inhibitory 
effects of ammonia on respiratory energy metabolism and mitochondrial function (Izumi et 
al., 2005). In these studies, mitochondrial function was measured using a mitochondrial 
dehydrogenase assay (Fig. 4). Incubation of the slices with 1 mM ammonia significantly 
reduced the production of the formazan end product. This reduction in enzymatic activity 
was overcome by co-administration of 1 mM L-carnitine, while L-carnitine itself did not 
facilitate formazane formation.  
 
Fig. 4. (from Izumi et al., 2005). Effects of ammonia and L-carnitine on mitochondrial 
function. The WST-1 mitochondrial dehydrogenase assay (optical density measurements at 
420 nm) was performed 1 h after pre-incubation with ammonia in the absence and presence 
of L-carnitine. P** < 0.01 by paired Student’s t test.  
Similarly, DL-APV, an antagonist of NMDA receptors, diminished the effects of ammonia 
on reduced ATP levels and inhibition of long-term potentiation. These in vitro data suggest 
that L-carnitine and NMDA receptor antagonists have the potential to preserve neuronal 
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function during HA, confirming results obtained in vivo in hyperammonemic animals (see 
above). Minana et al. (2002) compared the in vivo and in vitro effects of different 
trimethylamine-containing compounds on ammonia toxicity in mice and against glutamate 
and NMDA toxicity in primary cultures of neurons (Tables 1 and 2).  
 
Table 1. (adapted from Minana et al., 2002). Protective effect of different compounds against 
acute ammonia toxicity. Groups of mice were injected i.p. with the indicated doses of each 
compound. Fifteen minutes later, the mice were injected i.p. with 14 mmol/kg of 
ammonium acetate. All values are statistically different from mice injected only with 
ammonia. 
4.1.2.2 L-carnitine in human hepatic encephalopathy 
As mentioned above, experimental HA is not a model of human liver disease and rather 
serves to investigate the neurotoxicity of acute or chronic ammonia exposure or to study 
specific aspects of liver failure (Belanger & Butterworth, 2005). Therefore, very few studies 
that investigate the effects of L-carnitine in appropriate animal models of HE have been 
published. Clinical studies in humans with HE have only been performed by a few groups 
to date. Nevertheless, in initial clinical studies (del Olmo et al., 1990), the effect of L-carnitine 
on HA in patients with cirrhosis, subjected to a rectal ammonium overload test, was 
investigated. On comparing 40 cirrhotic patients given L-carnitine with 40 control cirrhotics 
given a placebo, no significant differences were observed in ammonium levels. However, on 
studying the patients with the greatest liver involvement, those given L-carnitine showed 
smaller elevations in ammonia and better responses to psychometric tests than those 
receiving the placebo. These data provided the first evidence on the effect of L-carnitine on 
ammonia clearance and pointed to the importance of further investigations. 
Survival
Compound Dose
Survivors/Injected %
nmol/kg
None 17/142 12
L-carnitine 16 24/28 86
D-carnitine 16 21/31 68
Betaine 16 12/20 60
TMAO 8 32/50 64
Choline 1.6 43/65 66
Acetylcholine 0.28 17/30 57
Acetylcholine 0.55 63/88 71
Carbachol 0.0028 14/30 46
Carbachol 0.0055 23/49 51
Acetylcarnitine 6 41/54 76
Isovalerylcarnitine 4 17/21 80
 
www.intechopen.com
 
L-carnitine in Hyperammonemia and Hepatic Encephalopathy 
 
377 
 
Table 2. (adapted from Minana et al., 2002). Effects of trimethylamine-containing com-
pounds on neuronal death induced by glutamate or NMDA. Neurons were incubated with 
these compounds for 15 min and then 1 mM glutamate or 0.5 mM NMDA was added to the 
plates. Neuronal survival was determined 4 h later by staining with fluorescein diacetate 
and propidium iodide.  
Based on previous experiments in animal models, such as the rat model of ammonia-
precipitated encephalopathy (Therrien et al., 1997), in a clinical randomized placebo-
controlled study, 120 patients with moderate HE due to cirrhosis were treated for 60 days 
with L-carnitine (2 g twice a day) (Malaguarnera et al., 2003). The study demonstrated a 
protective effect of L-carnitine in ammonia-precipitated encephalopathy in these patients 
after 30 days, which was more pronounced after 60 days of treatment. Concomitantly, a 
significant therapeutic effect of L-carnitine was observed in a psychometric test. Also, in 50 
patients infected with HCV and development of chronic hepatitis, the effect of L-carnitine 
on interferon (IFN)-alpha-induced fatigue was evaluated (Neri et al., 2003). Fatigue is a 
common complaint in patients with liver disease, and can be induced also by IFN. Patients 
treated with IFN and L-carnitine show a marked and early significant reduction of fatigue 
levels compared to untreated patients. It has been suggested from these data, taking into 
account the severity of this symptom in this study, that L-carnitine could be used as an 
energetic substrate in IFN-treated patients, leading to a better response to this side effect. 
However, the mechanisms by which L-carnitine might exert a protective effect based on 
energy metabolism still remain to be investigated. 
In 2005, Malaguarnera et al. continued to work with these data and evaluated the influence 
of L-carnitine on mental conditions and ammonia effects on patients with minimal or 
moderate HE due to different liver diseases, in a randomized, placebo-controlled study. The 
patients were randomized into an L-carnitine receiving group (2 g twice daily for 90 days) 
and a placebo-receiving group in a double-blind test. The results showed a protective effect 
of L-carnitine against ammonia-precipitated encephalopathy in cirrhotic patients, together 
with a significant decrease in ammonia fasting serum levels. After 30 days of treatment, 
Glutamate NMDA
Compound Dose
Surviving neurons
None 20   ± 8 28    ± 7
Carnitine 0.5 mM 70   ± 8 47    ± 8
Betaine 1 mM 69   ± 7 46    ± 5
TMAO 1 mM 75   ± 4 64    ± 12
Choline 1 mM 65   ± 5 41    ± 5
Acetylcholine 1 mM 68   ± 4 23    ± 11  NS
Carbachol 1 mM 73    ± 3 40    ± 6
Acetylcarnitine 1 µM 69   ± 3 48    ± 8
Trans-ACPD 0.1 mM 84   ± 6 65    ± 5
MK-801 20 nM 80   ± 5 83    ± 6 
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ammonia serum levels were significantly decreased, with an ongoing trend after 60 and 90 
days. Psychometric tests also clarified a significant therapeutic effect. 
Based on data suggesting a protective effect of L-carnitine on HA-induced neuronal 
dysfunction, eighteen cirrhotic patients with HE and HA received a single dose of 0.5 g 
acetyl-L-carnitine to investigate its effects on neuronal function (Siciliano et al., 2006). The 
effects of acute acetyl-L-carnitine administration were studied by pattern-reversal visual-
evoked potentials (VEP) to evaluate neuronal function. The results showed a rapid effect of 
a single dose of acetyl-L-carnitine. It was suggested that it transiently improves neuronal 
function in cirrhotic patients with persistent HE and HA. However, there was no change in 
plasma ammonia levels. In contrast to most animal studies, these results suggest a direct 
effect of acetyl-L-carnitine on the CNS with as yet unknown mechanisms. 
In another evaluation, Malaguarnera et al. (2006) investigated the efficacy of acetyl-L-
carnitine in the treatment of hepatic coma in a randomized placebo-controlled study. The 
patients received either acetyl-L-carnitine or a placebo (4 g intravenously over 3 hours, once 
a day for 3 days). A significant improvement in neurological symptoms and decrease in EEG 
grade, together with a reduction of ammonia plasma levels, were obvious at 1 to 4 hours 
after treatment and remained until 24 hours after. An extended study by Malaguarnera et al. 
(2008) evaluated the cognitive function of 125 cirrhotic patients with minimal HE after 
treatment with acetyl-L-carnitine (2 g twice a day for 90 days). These results showed a 
considerable improvement in neuropsychological functions and a significant reduction in 
serum ammonium levels, further confirming neuronal improvements after L-carnitine 
treatment. 
4.1.2.3 Preliminary results on metabolic alterations using multinuclear NMR spectroscopy 
High-resolution Nuclear Magnetic Resonance (NMR) approaches using stable isotopes are 
now yielding large amounts of detailed information on cerebral metabolic 
compartmentalization and neuronal-glia interactions (Zwingmann & Leibfritz, 2003). In 
order to investigate the effect of L-carnitine on energy metabolism, 1H- and 13C-NMR 
spectroscopy was used to measure metabolic pathways in brain and muscle following 
administration of [U-13C]glucose (500 mg/kg; i.p.) to rats with mild HE and in rats with 
ammonia-precipitated encephalopathy. As a model of mild HE, we investigated rats four 
weeks after an end-to-side portacaval anastomosis (PCA). During the last 7 days, rats with 
PCA and controls were administered daily either L-Carnitine (0.8 mmol/kg; i.p.) or saline. 
After administration of  [U-13C]glucose for 15 to 60 minutes, the rats were sacrificed. The 
frozen tissue samples of brain and muscle were powdered over liquid nitrogen and 
homogenized in perchloric acid (PCA) at 0ºC. Homogenates were centrifuged, the 
supernatants neutralized, precipitated KClO4 sedimented, and the supernatants lyophilized. 
The lyophilized samples were dissolved in 600 µl D2O, centrifuged and neutralized (pH = 
6.8). The pellet after the first centrifugation step was homogenized in water and lyophilized. 
The lyophilized samples were dissolved in 800 µl CDCl3/CD3OD to obtain the fatty acid 
components. All animals received humane care according to the criteria outlined in the 
“Guide for the Care and Use of Laboratory Animals” prepared by the National Academy of 
Sciences and published by the National Institutes of Health (NIH publication 6-23 (revised), 
1985). 
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As a neurobehavioral measure, locomotor activities were measured using a computerized 
Auto-Track system (Columbus Instruments, OH), consisting of a 15-by-15 infrared beam 
array with an interbeam distance of 2.4 cm along the X and Y axis. Data were collected every 
0.1 s and the activity was categorized as ambulatory, stereotypic, or resting. The animal 
activity meter was installed in a quiet isolated room with 12 h light/12 h dark cycles. One 
hour after HAL, the animals were placed individually in the auto-track system and data 
acquisition was started for a period of 24 hr. PCA in the rat resulted in a broad spectrum of 
neurobehavioral changes, such as an 80% impaired locomotor activity, which was largely 
prevented by L-carnitine (Fig. 5). 
 
Fig. 5. Night and day locomotor activity in rats with PCA with or without treatment with L-
carnitine.  
Stable isotope spectroscopic methods make it possible to measure the output of interrelated 
pathways concurrently and determine several atoms (e.g. 1H and 13C) without 
transformation or isolation processes (Zwingmann & Leibfritz, 2003). The metabolic 
pathways by which the 13C-label from [1-13C]glucose is transformed into various metabolites 
are presented in simplified form in Fig. 6. For a more detailed description of the metabolic 
pathways from 13C-labelled glucose isotopomers, see Zwingmann & Leibfritz (2003). Briefly, 
via the glycolytic pathway, [1-13C]glucose is transformed into [3-13C]pyruvate, [3-13C]alanine 
and [3-13C]lactate. [3-13C]pyruvate may enter the TCA cycle via the anaplerotic pathway 
(pyruvate carboxylase, PC (or malic enzyme (ME)) or the oxidative pathway (pyruvate 
dehydrogenase, PDH). Via PC, glutamate and glutamine are labelled at C-2. In the oxidative 
pathway, pyruvate enters the cycle as [2-13C]acetyl-CoA, and glutamate and glutamine are 
mono-labelled at C-4. 
The data show that PCA in rats resulted in a decreased flux through PDH, a key enzyme for 
mitochondrial metabolism, which is primarily present in the neurons. Concomitant 
treatment with L-carnitine eliminated this effect over the levels of sham-operated controls 
(Fig. 7).  
Another group of rats received ammonium acetate (3.8 mmol/kg; i.p.) four weeks after PCA 
to precipitate encephalopathy. L-carnitine was concomitantly administered in a single dose 
(1.6 mmol/kg; i.p.). In rats with ammonia-precipitated encephalopathy, treatment with L-
carnitine delayed the time to the onset of coma (Fig. 8). Animals in which both righting 
ability and corneal reflex were affected were considered to be in coma. Rats with ammonia-
precipitated encephalopathy and rats treated with L-carnitine were sacrificed at the same 
time points.  
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Fig. 6. Labelling of metabolites from [1-13C]glucose. Label distribution in glycolytic and TCA 
cycle intermediates during metabolism of [1-13C]glucose. A single turn of the TCA cycle 
from pyruvate via PC (pyruvate carboxylase) or PDH (pyruvate dehydrogenase) to 2-
oxoglutarate and subsequently glutamate and glutamine is considered. A description of the 
pathways leading to the different isotopomers is provided in the text. LDH: lactate 
dehydrogenase; ALAT: alanine aminotransferase; GDH: glutamate dehydrogenase; GS: 
glutamine synthetase. 
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Fig. 7. Effect of L-carnitine on mitochondrial metabolism in rats with mild HE.  
[U-13C]glucose flux through the Krebs cycle was measured by the de novo synthesis of 
glutamate through PDH 12 hours after the last administration of L-carnitine or saline. 
 
Fig. 8. Time to the onset of coma in rats with ammonia-precipitated encephalopathy.  
Elevated brain lactate is a phenomenon which is characteristic of both human and 
experimental HE. As an indirect measurement of mitochondrial Krebs cycle metabolism, we 
measured the de novo synthesis of lactate from 13C-labelled glucose in rats with ammonia-
precipitated encephalopathy without and with treatment with L-carnitine (Fig. 9). The data 
showed that treatment with L-carnitine significantly eliminated the rise in brain lactate in 
these animals.  
These preliminary data demonstrate that in chronic HE, L-carnitine acts on both brain and 
muscle by improving mitochondrial metabolism. These data further demonstrate that L-
carnitine prevents increased lactate synthesis in ammonia-precipitated encephalopathy, 
which parallels a significant increase in the time to coma. 
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Fig. 9. Effect of L-carnitine on glycolytic lactate synthesis in rats with ammonia-precipitated 
encephalopathy. [U-13C]glucose flux through glycolysis was measured by the de novo 
synthesis of lactate. 
5. Concluding remarks 
To date, few studies have investigated the effect of L-carnitine and its derivates in human 
hyperammonemic syndromes and HE. However, in hyperammonemic animal models and 
ammonia-exposed cultured neurons L-carnitine has been shown to counteract some of the 
neurotoxic effects of ammonia. These data clearly show that L-carnitine is able to reduce 
ammonia levels, increase energy metabolism and decrease mortality. These studies further 
prove that HA is a key factor in HE. A protective effect of L-carnitine against disordered 
mental function and ammonia-precipitated encephalopathy was also observed in cirrhotic 
patients with HE, together with lowered circulating ammonia levels. These clinical trials are 
promising as they clarify that L-carnitine can reduce ammonia levels and improve patient 
performance in HE. The molecular mechanisms of the action of L-carnitine have not yet 
been fully elucidated, although the results suggest an effect on neuronal function in HE.  
HE is a disorder that morphologically primarily affects the astrocytes (Norenberg, 1998). 
The dysfunction of astrocytes includes deficits in their ability to take up glutamate from the 
extracellular space, which may lead to abnormal glutamatergic neurotransmission. 
However, a series of studies has also demonstrated that ammonia directly causes disorders 
in neuronal function and neurotransmitter homeostasis by acting on glutamatergic receptors 
and by synthesis of neurotransmitters, i.e. glutamate and GABA. Furthermore, in recent 
studies an inhibition of neuronal energy metabolism in the TCA cycle has been proposed. 
Animal and cell culture studies have indicated that ammonia impairs neuronal function via 
altered metabolism and ultimately NMDA receptor activation, and that L-carnitine and 
NMDA receptor antagonists have the potential to preserve neuronal function during HA. L-
carnitine and its derivates increase energy metabolism via the TCA cycle by activation of 
fatty acid oxidation. They are able to change the activities of several enzymes involved in 
fatty acid metabolism, increase the synthesis of phospholipids and provide acetyl groups for 
the synthesis of acetylcholine. Furthermore, they can modify membrane fluidity and surface 
charge, which lead to altered activity of membrane transporter and enzymes. Since the brain 
can sustain part of its energy metabolism by fatty acid catabolism, the role of astrocytes and 
their energy metabolism in L-carnitine therapy needs further experimental clarification. 
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The treatment of HA is uncertain and mostly directed to reducing the level of circulating 
ammonia. There is currently no therapy designed to counteract the molecular effects of 
ammonia. A further question remains as to whether the protective effects of L-carnitine 
against the toxicity of ammonia are systemic. In most studies, L-carnitine reduces circulating 
ammonia levels, suggesting a systemic effect of L-carnitine. For example, L-carnitine has 
been shown to have direct effects on the liver in patients with steatosis (Romano et al., 2008), 
and Benzerrouk and Qureshi (2001) demonstrated that acetyl-L-carnitine has a modulating 
effect on several hepatic mitochondrial matrix and inner membrane proteins that are 
modified by HA in the spf mutant mouse. On the other hand, L-carnitine seems to have 
direct effects on cerebral metabolism in valproic acid toxicity in the absence of 
hepatocellular dysfunction (Sztajnkrycer, 2002). 
Another question to be clarified is why the effects of L-carnitine differ from its derivative 
acetyl-L-carnitine. When compared with L-carnitine, for example, acetyl-L-carnitine better 
preserved ATP in the brain of hyperammonemic mice, while it lowered ammonia in the 
blood and brain less markedly. One reason for this apparent discrepancy may lie in the use 
of the acetyl residue by the brain. This, on the other hand, points to an additional effect of 
this L-carnitine derivative on astrocytic energy metabolism, since acetate is taken up 
selectively by astrocytes while neurons do not use acetate (Waniewski and Martin, 1998; 
Zwingmann & Leibfritz, 2003). On the other hand, there could be a close correlation 
between changes in astrocytic energy metabolism and neuronal (dys)function. In particular, 
L-carnitine exerts its effects in part by changes in NMDA receptor activation. Ammonia and 
extracellular glutamate cause an overactivation of this receptor, which in turn produces NO 
resulting in nitration-mediated inhibition of proteins such as the ammonia-detoxifying 
glutamine synthetase in the astrocytes. Improved energy metabolism in the astrocytes might 
counteract this deficit as well as a possible effect of ammonia on the astrocytic TCA cycle 
(Chatauret et al., 2003). The molecular and cell-specific energetic effects of L-carnitine and 
acetyl-L-carnitine therefore require further clarification.  
Taken together, these results show that L-carnitine and its analogues do have the potential 
to suppress the neurotoxicity of ammonia. The fact that the action of acetyl-L-carnitine may 
differ from that of L-carnitine suggests that the classical function of L-carnitine is not the 
sole mechanism underlying the suppression of the neurotoxicity of ammonia (Matsuoka & 
Igisu, 1993). However, further investigations are required to clarify the molecular 
mechanisms that lead to the protective effects of L-carnitine and its derivates in both 
experimental HA and human HE. Other studies may also optimize the dosage and time of 
administration of L-carnitine. Analysis of selected L-carnitine trials compared to currently 
accepted therapies suggests that L-acyl-carnitine is promising as a safe and effective 
treatment for HE, and further trials of this drug are warranted (Shores & Keeffe, 2008). Since 
it is a low-cost agent with few side effects, further clinical trials could prove to be promising 
in evaluating the broader use of L-carnitine and derivatives in patients with minimal or 
ammonia-precipitated HE. 
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